Entscheid und Zulassungsgesuch, Biogen, Wirkstoff Aducanumab
Sehr geehrte Europäische Arzneimittel-Agentur,
Auf Basis der Informationsfreiheit in den EU-Verträgen, verbrieft in Verordnung 1049/2001, beantrage ich Dokumente, welche folgende Informationen enthalten:
- Zulassungsgesuch der Firma Biogen für den Wirkstoff Aducanumab
- dazugehöriger Entscheid der Europäischen Arzneimittel-Agentur
Mit freundlichem Gruß,
Lukas Lippert
Delivery has failed to these recipients or groups:
[1]Dokumente requests at EMA ([EMA request email])
The email address you entered couldn't be found. Please check the
recipient's email address and try to resend the message. If the problem
continues, please contact your helpdesk.
Diagnostic information for administrators:
Generating server: wv1275.emea.eu.int
[EMA request email]
Remote Server returned '550 5.1.1 RESOLVER.ADR.RecipNotFound; not found'
Original message headers:
Received: from wv1275.emea.eu.int (172.16.91.20) by wv1275.emea.eu.int
(172.16.91.20) with Microsoft SMTP Server (TLS) id 15.0.1497.32; Fri, 19 Aug
2022 11:22:21 +0200
Received: from mail6.bemta32.messagelabs.com (172.16.40.221) by
wv1275.emea.eu.int (172.16.91.20) with Microsoft SMTP Server (TLS) id
15.0.1497.32 via Frontend Transport; Fri, 19 Aug 2022 11:22:21 +0200
Authentication-Results: mx.messagelabs.com; spf=pass
(server-18.tower-564.messagelabs.com: domain of asktheeu.org designates
93.93.128.121 as permitted sender) smtp.mailfrom=asktheeu.org; dkim=none
(message not signed); dmarc=none (no record) header.from=asktheeu.org
X-Brightmail-Tracker: H4sIAAAAAAAAA+NgFlrMIsWRWlGSWpSXmKPExsUSG9tQqesb9j/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X-Env-Sender: [FOI #11755 email]
X-Msg-Ref: server-18.tower-564.messagelabs.com!1660900940!135638!1
X-Originating-IP: [93.93.128.121]
X-SpamReason: No, hits=0.0 required=7.0 tests=newsletters:
X-StarScan-Received:
X-StarScan-Version: 9.87.3; banners=-,-,-
X-VirusChecked: Checked
Received: (qmail 26855 invoked from network); 19 Aug 2022 09:22:21 -0000
Received: from mslb001sova.srv.mysociety.org (HELO mslb001sova.srv.mysociety.org) (93.93.128.121)
by server-18.tower-564.messagelabs.com with ECDHE-RSA-AES256-GCM-SHA384 encrypted SMTP; 19 Aug 2022 09:22:21 -0000
Received: from mstr002sova.srv.mysociety.org ([2a00:1098:80:3b::d:1]:39596)
by mslb001sova.srv.mysociety.org with esmtps (TLS1.3) tls TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384
(Exim 4.94.2)
(envelope-from <[FOI #11755 email]>)
id 1oOyCq-0033Nf-HR
for [EMA request email]; Fri, 19 Aug 2022 09:22:20 +0000
Received: from foieu by mstr002sova.srv.mysociety.org with local (Exim 4.94.2)
(envelope-from <[FOI #11755 email]>)
id 1oOyCq-009liu-6i
for [EMA request email]; Fri, 19 Aug 2022 09:22:20 +0000
Date: Fri, 19 Aug 2022 09:22:20 +0000
From: Lukas Lippert <[FOI #11755 email]>
To: Dokumente requests at EMA <[EMA request email]>
Message-ID: <[email address]>
Subject: Informationsfreiheit Anfrage - Entscheid und Zulassungsgesuch,
Biogen, Wirkstoff Aducanumab
MIME-Version: 1.0
Content-Type: text/plain; charset="UTF-8"
Content-Transfer-Encoding: quoted-printable
Return-Path: [FOI #11755 email]
References
Visible links
1. mailto:[EMA request email]
Dear European Medicines Agency,
The response to my request has been delayed. By law, you should normally have responded at latest by September 09, 2022. I hope my request will be answered now as quickly as possible.
Yours faithfully,
Lukas Lippert
Delivery has failed to these recipients or groups:
[1]documents requests at EMA ([EMA request email])
The email address you entered couldn't be found. Please check the
recipient's email address and try to resend the message. If the problem
continues, please contact your helpdesk.
Diagnostic information for administrators:
Generating server: wv1275.emea.eu.int
[EMA request email]
Remote Server returned '550 5.1.1 RESOLVER.ADR.RecipNotFound; not found'
Original message headers:
Received: from wv1277.emea.eu.int (172.16.91.22) by wv1275.emea.eu.int
(172.16.91.20) with Microsoft SMTP Server (TLS) id 15.0.1497.32; Mon, 12 Sep
2022 09:09:22 +0200
Received: from mail6.bemta34.messagelabs.com (172.16.40.221) by
wv1277.emea.eu.int (172.16.91.22) with Microsoft SMTP Server (TLS) id
15.0.1497.32 via Frontend Transport; Mon, 12 Sep 2022 09:09:22 +0200
Authentication-Results: mx.messagelabs.com; spf=pass
(server-11.tower-584.messagelabs.com: domain of asktheeu.org designates
93.93.128.121 as permitted sender) smtp.mailfrom=asktheeu.org; dkim=none
(message not signed); dmarc=none (no record) header.from=asktheeu.org
X-Brightmail-Tracker: H4sIAAAAAAAAA+NgFlrNIsWRWlGSWpSXmKPExsUSG9tQqat4Wy7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X-Env-Sender: [FOI #11755 email]
X-Msg-Ref: server-11.tower-584.messagelabs.com!1662966561!803971!1
X-Originating-IP: [93.93.128.121]
X-SpamReason: No, hits=0.0 required=7.0 tests=newsletters:
X-StarScan-Received:
X-StarScan-Version: 9.87.3; banners=-,-,-
X-VirusChecked: Checked
Received: (qmail 3733 invoked from network); 12 Sep 2022 07:09:21 -0000
Received: from mslb001sova.srv.mysociety.org (HELO mslb001sova.srv.mysociety.org) (93.93.128.121)
by server-11.tower-584.messagelabs.com with ECDHE-RSA-AES256-GCM-SHA384 encrypted SMTP; 12 Sep 2022 07:09:21 -0000
Received: from mstr002sova.srv.mysociety.org ([2a00:1098:80:3b::d:1]:53646)
by mslb001sova.srv.mysociety.org with esmtps (TLS1.3) tls TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384
(Exim 4.94.2)
(envelope-from <[FOI #11755 email]>)
id 1oXdZJ-0058Aw-6s
for [EMA request email]; Mon, 12 Sep 2022 07:09:21 +0000
Received: from foieu by mstr002sova.srv.mysociety.org with local (Exim 4.94.2)
(envelope-from <[FOI #11755 email]>)
id 1oXdZI-0012lP-RP
for [EMA request email]; Mon, 12 Sep 2022 07:09:20 +0000
Date: Mon, 12 Sep 2022 07:09:20 +0000
From: Lukas Lippert <[FOI #11755 email]>
To: documents requests at EMA <[EMA request email]>
Message-ID: <[email address]>
Subject: Re: access to documents request - Entscheid und Zulassungsgesuch,
Biogen, Wirkstoff Aducanumab
MIME-Version: 1.0
Content-Type: text/plain; charset="UTF-8"
Content-Transfer-Encoding: 7bit
Return-Path: [FOI #11755 email]
References
Visible links
1. mailto:[EMA request email]